Incyte Q3 2026: revenue up 14% to $1.56B, but a $1.23B Vega deal charge drove a $785M loss

Incyte's third quarter of 2026 (three months to September 30) has two stories that point in opposite directions. The business grew: total revenue rose 14.0% to $1,557.2 million and net product sales rose 14% to $1,316.4 million, with the drugs that are not Jakafi doing most of the work. But the company reported a net loss of $784.8 million, or $3.86 per diluted share, against a $424.2 million profit ($2.11) a year earlier. The loss comes almost entirely from one accounting entry: a one-time $1.23 billion charge for buying Vega Therapeutics, the owner of a late-stage drug for the bleeding disorder von Willebrand disease. Excluding that charge, the company says GAAP operating income rose 18%. Management also raised its full-year sales guidance for the second quarter in a row.

Q3 2026 in numbers

Operating margin is the share of revenue left after running the business (product costs, research and selling expenses), before interest and tax. "n/m" means the percentage change is not meaningful because the figure swung from a profit to a loss.

Where the growth came from

Jakafi (a ruxolitinib pill for the bone-marrow cancers myelofibrosis and polycythemia vera, and for graft-versus-host disease) grew 4% to $826.5 million. The release attributes this to "a 12% increase in paid demand and growth across all indications" and says wholesaler inventory was "within normal range", so distributors were not stocking up. The gap between 12% more demand and 4% more sales means the net price per unit fell. The release does not break out the price effect this quarter (Q2's 10-Q showed volume adding $66.3 million and lower net price taking away $13.4 million). Jakafi sales now include Jakafi XR, the once-daily version launched in Q2.

Opzelura (ruxolitinib cream for eczema and vitiligo) rose 36% to $254.9 million. The release credits more patients in both conditions plus "improvements in net pricing resulting from the Opzelura line extension settlement in the second quarter". That settlement with CMS, the federal agency that runs Medicare and Medicaid, means Opzelura no longer owes the larger Medicaid rebates tied to Jakafi's pricing history. In Q2 it produced a one-time $246.0 million revenue gain. There is no such one-off in Q3, but the lower rebate rate keeps lifting each quarter's net price, so part of the 36% is pricing and not just more prescriptions.

Hematology & Oncology rose 38% to $235.0 million. All of the growth came from three newer drugs. Niktimvo (chronic graft-versus-host disease) rose 47% to $67.4 million. Zynyz (anal and Merkel cell cancers) rose 157% to $58.3 million. Monjuvi/Minjuvi (lymphoma) rose 30% to $54.6 million. Together those three grew 63%. The two older drugs in the group fell: Iclusig was down 11% to $33.5 million and Pemazyre down 7% to $21.2 million.

Royalties from drugs Incyte licensed to other companies rose 11.6% to $191.0 million. Most of that is Jakavi (Novartis's name for Jakafi outside the US) at $132.5 million (+5%), plus Eli Lilly's Olumiant at $39.1 million (+5%). Milestone payments from partners were $49.8 million, versus $45.0 million.

The Vega charge and spending

In July Incyte completed its $1.25 billion purchase of Vega Therapeutics. The deal brought in latarcibart, a once-a-month injection now in a Phase 3 trial (VIVID-6) for von Willebrand disease, with topline data expected in early 2029. Star Therapeutics, the seller, can earn up to $750 million more if sales milestones are hit. Because latarcibart is not yet approved, about $1.23 billion of the price was booked as an R&D expense this quarter.

That is why GAAP R&D jumped 254% to $1,791.7 million. Excluding the Vega charge, the release says R&D rose 11%, "primarily reflecting increased investment in our late stage development assets." Selling, general and administrative costs (SG&A) rose 11% to $364.3 million "primarily due to pre-launch activities", meaning preparation for the launches management expects in early 2027. Cost of sales stayed at 8% of net product sales ($108.7 million).

What the headline numbers hide

• The loss is a one-time accounting cost, not an operating problem. Add back the roughly $1.23 billion Vega charge and GAAP operating income is about $520 million. That is up 18% on the company's own count, against $443.5 million a year ago, and the operating margin is about 33.5% versus 32.5%. So the underlying business made a slightly higher margin while also funding pre-launch spending.
• GAAP vs adjusted is a small gap here. Incyte's non-GAAP figures remove only stock-based compensation ($69.8M), amortization of the acquired Iclusig rights ($5.4M), a $13.2M loss on equity investments, a $0.9M change in an acquisition liability and $2.6M of Vega transition costs, minus their tax effect. They do not remove the IPR&D charge. That is why adjusted EPS is –$3.60 against GAAP –$3.86, a 26-cent gap. Unlike many drugmakers, Incyte's "adjusted" number does not hide deal costs.
• A tax bill on a loss. Incyte recorded a $96.0 million income-tax expense on a $688.8 million pre-tax loss. The release does not explain the tax treatment of the Vega charge. A positive tax bill on a loss suggests the charge brought little or no tax benefit, which makes the net loss deeper than the operating loss alone would suggest.
• Smaller swings in "other" items. A $13.2 million loss on equity investments replaced an $8.6 million gain, and a $12.2 million gain on an acquisition liability a year ago did not repeat. Together these make the comparison about $35 million harsher before tax. Interest income rose to $32.2 million from $26.8 million.
• Cash conversion can't be checked directly. The earnings release has no cash-flow statement; that comes with the 10-Q. Cash, cash equivalents and marketable securities were $3.85 billion at September 30, up from $3.58 billion at December 31, even though the $1.25 billion Vega purchase closed during the period. Accounts receivable rose 21% since year-end to $1,237.0 million, slightly slower than the 25% rise in nine-month net product sales. Inventory rose 7% to $475.8 million.
• No buyback effect. The release reports no share repurchases or dividends. Basic shares rose 3.9% to 203.2 million, so the share count is growing, not shrinking. Diluted shares were +0.9%, but that comparison is distorted: in a loss quarter, options are left out of the diluted count.
• Guidance went up again. Total net sales guidance moved to $5,210–5,300 million from $5,130–5,260 million. Opzelura and Hematology & Oncology were raised. Jakafi and expense guidance were left unchanged.

On balance the quarter is understated: a one-time ~$1.23 billion IPR&D charge for the Vega acquisition turned an operating profit that grew about 18% into a $708 million operating loss and a $3.86-per-share net loss.

Did last time's read hold up?

Our Q2 2026 report expected Q3 GAAP results to "very likely show a large loss" because of an IPR&D charge of about $1,270 million. That happened, with a charge of about $1.23 billion. It also said the test was whether Opzelura and the newer drugs could keep growing fast enough before Jakafi's 2028 patent expiries. They did: non-Jakafi product sales grew 37%. Opzelura's growth sped up from about 24% (underlying) in Q2 to 36%, helped by better pricing after the settlement. The hematology/oncology group slowed from 69% to 38%. We noted that Jakafi's guidance implied $1,646–1,696 million in the second half. Q3's $826.5 million is in line with that.

Guidance and outlook

What the guidance implies for Q4, using the nine-month figures in the release:

• Total net product sales: $1,301–1,391 million, against Q3's $1,316.4 million, so roughly flat to up 6% from Q3.
• Jakafi: $819–869 million, consistent with steady growth.
• Opzelura: $252–272 million.
• GAAP R&D + SG&A: about $1,046–1,126 million, compared with roughly $926 million in Q3 once the Vega charge is removed. Spending is expected to step up, probably for the pre-launch work and new Phase 3 starts, so Q4's operating margin will likely be lower than Q3's underlying ~33%.

The release does not discuss Jakafi generic competition this quarter. The CEO's emphasis on "a durable core business beyond Jakafi" and "multiple paths to growth beyond 2029" is the same bet described in the Q2 10-Q, where Incyte said its main ruxolitinib patents expire in mid and late 2028. The near-term events that decide whether that bet pays off:

• Phase 3 results by year-end for povorcitinib in prurigo nodularis and Opzelura cream in hidradenitis suppurativa, a painful skin disease.
• An EU decision on povorcitinib in hidradenitis suppurativa in Q4 2026, after a positive recommendation from the EU's medicines committee (CHMP).
• Potential US approvals in Q1 2027 for povorcitinib in hidradenitis suppurativa and for Monjuvi in newly diagnosed diffuse large B-cell lymphoma.
• A Phase 3 study (EXCALIBUR-MF2) of the CALR antibody INCA033989 in myelofibrosis, expected to start by year-end.

Another strategic change: Incyte stopped enrolling a Phase 3 study of its CDK2 drug in platinum-resistant ovarian cancer and is moving it to first-line maintenance treatment instead.

Takeaway: Ignore the $3.86 loss: it is the accounting cost of buying a Phase 3 drug, and Incyte's own adjusted figures show it too. The number that matters is $490 million of non-Jakafi sales, up 37% and now 37% of product sales. At that pace the post-2028 gap is closing, but Jakafi still brings in 63% of product sales, and its 12% demand growth is turning into only 4% sales growth.

Source: Incyte Q3 2026 earnings release, Form 8-K Exhibit 99.1 (October 29, 2026). The full 10-Q, with the cash-flow statement and segment detail, had not been filed at the time of writing. Figures excluding the Vega charge use the company's stated $1.23 billion and are approximate. The comparison with Q2 draws on our earlier report and Incyte's Q2 10-Q.